Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cerdulatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK known ✓ | P43405 | 20/20 | 1.00 |
| ▸ | JAK1 known ✓ | P23458 | 3/20 | 1.00 |
| ▸ | TYK2 known ✓ | P29597 | 2/20 | 1.00 |
| ▸ | JAK3 known ✓ | P52333 | 2/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | FLT3 | P36888 | 2/20 | 1.00 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 2/20 | 1.00 |
| ▸ | STK4 | Q13043 | 2/20 | 1.00 |
| ▸ | STK3 | Q13188 | 2/20 | 1.00 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 1.00 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 1.00 |
| ▸ | RPS6KA6 | Q9UK32 | 2/20 | 1.00 |
| ▸ | JAK2 | O60674 | 2/20 | 1.00 |
| ▸ | NUAK1 | O60285 | 1/20 | 1.00 |
| ▸ | CSF1R | P07333 | 1/20 | 1.00 |
| ▸ | FLT4 | P35916 | 1/20 | 1.00 |
| ▸ | MAP3K9 | P80192 | 1/20 | 1.00 |
| ▸ | ITK | Q08881 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cerdulatinib SCHEMBL29462019 | 0.99 | SYK (1.00) | SYKJAK1CHEK1RETTYK2 | |
| SCHEMBL737349 | 0.92 | SYK (1.00) | SYKJAK1CHEK1RETTYK2 | |
| SCHEMBL8737323 | 0.92 | SYK (0.85) | SYKJAK1CHEK1RETTYK2 | |
| SCHEMBL20734854 | 0.92 | SYK (0.85) | SYKJAK1CHEK1RETTYK2 | |
| SCHEMBL21554052 | 0.91 | SYK (0.83) | SYKJAK1CHEK1RETTYK2 | |
| SCHEMBL736830 | 0.91 | SYK (1.00) | SYKJAK1CHEK1RETTYK2 | |
| SCHEMBL21554059 | 0.91 | SYK (0.82) | SYKJAK1CHEK1RETTYK2 | |
| SCHEMBL21554086 | 0.90 | SYK (0.82) | SYKJAK1CHEK1RETTYK2 | |
| SCHEMBL17076550 | 0.89 | SYK (0.81) | SYKJAK1CHEK1RETTYK2 | |
| SCHEMBL22030443 | 0.89 | SYK (0.81) | SYKJAK1CHEK1RETTYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2292 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137953-A1 | METHOD FOR TARGETED TREATING DERMATOSES | STRATA SKIN SCIENCES INC. (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026090557-A1 | SYSTEMS AND METHODS FOR PROCESSING ISM AND MCAS CLINICAL TRIAL DATA | TELIOS PHARMA INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-12611408-B2 | Methods for treating nail brittleness, fragility, or pitting | CHEMISTRY RX (US) | 2026-04-28 | — | — | US | claimed |
| US-20260097056-A1 | SYK ACTIVATORS AND INHIBITORS IN NEURODEGENERATIVE DISEASES | UNIV VIRGINIA PATENT FOUNDATION (US) | 2026-04-09 | — | — | US | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-20260008791-A1 | CHEMICAL COMPOUNDS | BORAH INC (US) | 2026-01-08 | — | — | US | claimed |
| US-20260008856-A1 | METHODS OF TREATING DISEASE USING ANTI-IL1RAP ANTIBODIES AND ANTIBODY DRUG CONJUGATES | BLUEFIN BIOMEDICINE INC (US) | 2026-01-08 | — | — | US | claimed |
| US-20250382312-A1 | BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | BORAH INC (US) | 2025-12-18 | — | — | US | claimed |
| US-20250367113-A1 | DRUG DELIVERY SYSTEM COMPRISING AN ANTI-INFLAMMATORY AGENT OR A SALT THEREOF FOR THE APPLICATION TO ESOPHAGEAL MUCOUS MEMBRANES | ESOCAP AG (CH) | 2025-12-04 | — | — | US | claimed |
| EP-4640714-A2 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML Screening, LLC (US) | 2025-10-29 | — | — | EP | claimed |
| EP-3942045-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | ONXEO (FR) | 2022-01-26 | — | — | EP | claimed |
| WO-2019113475-A1 | TOPICAL OINTMENT FORMULATIONS AND THEIR USE IN TREATING SKIN CONDITIONS | Dermavant Sciences GmbH (CH) | 2019-06-13 | — | — | WO | claimed |
| WO-2018189566-A1 | USE OF A CHEMICAL COMPOUND AS A THERAPEUTIC AGENT | BEVEC DORIAN (DE) | 2018-10-18 | — | — | WO | claimed |
| EP-3191098-A1 | COMBINATIONS AND DOSING REGIMES TO TREAT RB-POSITIVE TUMORS | G1 Therapeutics, Inc. (US) | 2017-07-19 | — | — | EP | claimed |
| EP-2321283-B1 | 2,6-DIAMINO-PYRIMIDIN-5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS | PORTOLA PHARM INC (US) | 2016-07-13 | — | — | EP | claimed |
| WO-2016040858-A1 | COMBINATIONS AND DOSING REGIMES TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | claimed |
| CN-102066340-B | 2, 6-diamino-pyrimidin- 5-yl-carboxamides as SRK or JAK kinases inhibitors | PORTOLA PHARM INC | 2014-05-14 | — | — | CN | claimed |
| US-20130237493-A1 | COMBINATION THERAPY OF 4-(CYCLOPROPYLAMINO)-2-(4-(4-(ETHYLSULFONYL)PIPERAZIN-1-YL)PHENYLAMINO)PYRIMIDINE-5-CARBOXAMIDE AND FLUDARABINE | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-09-12 | — | — | US | claimed |
| EP-2621489-A1 | COMBINATIONS OF 4-(CYCLOPROPYLAMINO)-2-(4-(4-(ETHYLSULFONYL)PIPERAZIN-1-YL)PHENYLAMINO)PYRIMIDINE-5-CARBOXAMIDE AND FLUDARABINE | Portola Pharmaceuticals, Inc. (US) | 2013-08-07 | — | — | EP | claimed |
| WO-2012045020-A1 | COMBINATIONS OF 4-(CYCLOPROPYLAMINO)-2-(4-(4-(ETHYLSULFONYL)PIPERAZIN-1-YL)PHENYLAMINO)PYRIMIDINE-5-CARBOXAMIDE AND FLUDARABINE | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-04-05 | — | — | WO | claimed |